CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)
Phase 2
Not yet recruiting
- Conditions
- DLBCL
- Interventions
- Drug: CDR-CHOP
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT06750991
- Locations
- 🇨🇳
No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai, Shanghai, China
Dynamic CtDNA-guided Targeted Therapy in DLBCL
Phase 2
Not yet recruiting
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Drug: R-CHOP + X
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 108
- Registration Number
- NCT06748521
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
Recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06746194
- Locations
- 🇨🇳
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine, Shanghai, Shanghai, China
Effect of Belimumab on Antibody Titers in Primary APS Patients
Phase 2
Recruiting
- Conditions
- Antiphospholipid Syndrome (APS)
- Interventions
- Drug: Belimumab+SOCDrug: SOC
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06747312
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study
Not yet recruiting
- Conditions
- T-NK Cell Lymphoma
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06747299
- Locations
- 🇨🇳
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine, Shanghai, Shanghai, China
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT06747156
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients
Recruiting
- Conditions
- α-synucleinopathyParkinson's Disease (PD)Multiple System AtrophyRapid Eye Movement Sleep Behavior DisorderPET
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06738862
- Locations
- 🇨🇳
Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
The Value of 68Ga-FAPI PET/CT in Preoperative Evaluation of Thyroid Cancer with Lymph Node Metastases
Recruiting
- Conditions
- Thyroid Cancer
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06730529
- Locations
- 🇨🇳
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine, Shanghai, Shanghai, China
Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After CABG
Phase 4
Not yet recruiting
- Conditions
- Coronary Artery Bypass Graft Surgery (CABG)Radial Artery GraftsGraft Failure
- Interventions
- Drug: Oral isosorbide mononitrate 4+ amlodipine
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT06730945
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Phase 2
Recruiting
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Biological: single dose of Inaticabtagene autoleucel
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06718244
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath